Banner
  • Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Failed Alzheimer's Trial Slaughters Elan

Article

Poor drug trial results sent the stocks of three companies down Tuesday morning when an experimental Alzheimer's treatment failed in the first of four big studies.

Poor drug trial results sent the stocks of three companies down Tuesday morning when an experimental Alzheimer’s treatment failed in the first of four big studies.

Pfizer, Johnson & Johnson and Elan Corp.’s bapineuzumab failed to improve the symptoms of dementia in its first big study. In this study, patients had a gene that made them more likely to get the disease. Other studies will focus on patients without the high genetic risk.

Of the three companies, Elan was hit the hardest, plummeting 15% at the opening bell. By midday the stock was trading at $11.50. Meanwhile, Pfizer and Johnson & Johnson fared a little better, dropping slightly more than 1%.

Elan Corp. stock on July 24, 2012

However, the failure wasn’t totally unexpected; researchers haven’t been too optimistic about the drug’s chances. An earlier ISI Group survey of more than 200 analysts revealed that two-thirds expected the drug to fail.

Eli Lilly, which is developing a drug similar to bapineuzumab, also fell in morning trading. By noon Lilly’s stock was down 5%. The same ISI survey revealed that Lilly’s drug is expected to fail too.

In May, Lundbeck’s experimental Alzheimer’s drug showed positive results, achieving significant improvement in cognition in a Phase II trial.

Read more:

The Race for an Alzheimer’s Blockbuster

“Safe Harbors” in a Volatile Market

Wells Fargo: A Warren Buffett-Approved Buy

Related Videos
Victor J. Dzau, MD, gives expert advice
Victor J. Dzau, MD, gives expert advice